Evidence map›Paper›PMID 36220070›Full record

ArticleCancer cell2022

A STING operation to expose KRAS and STK11 co-mutated lung cancers.

Ferdinandos Skoulidis, John V Heymach, Tina Cascone

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cancer cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ferdinandos SkoulidisDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: fskoulidis@mdanderson.org.
John V HeymachDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Tina CasconeDepartment of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: tcascone@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

KRAS and STK11 (LKB1) co-mutated (KL) tumors define an immunologically cold and anti-PD-(L)1-refractory non-small-cell lung cancer (NSCLC) subset. In this issue of Cancer Cell, Kitajima et al. outline a strategy to unleash innate immunity in KL tumors by utilizing epigenetic de-repression of STING and pulsed inhibition of spindle assembly checkpoint kinase MPS1.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAMP-Activated Protein Kinase KinasesHumansMutationProtein Serine-Threonine KinasesProto-Oncogene Proteins p21(ras)AMP-Activated Protein Kinase KinasesKRAS protein, humanProtein Serine-Threonine KinasesProto-Oncogene Proteins p21(ras)STK11 protein, human

Identifiers

PMID36220070
OpenAlexW4304014154

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.